Barrow Hanley Mewhinney & Strauss LLC Has $18.10 Million Holdings in Humana Inc. (NYSE:HUM)

Barrow Hanley Mewhinney & Strauss LLC decreased its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 88.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,336 shares of the insurance provider's stock after selling 566,499 shares during the quarter. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.06% of Humana worth $18,099,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Pinnacle Wealth Management Advisory Group LLC increased its position in Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after acquiring an additional 37 shares during the period. Mather Group LLC. grew its stake in shares of Humana by 21.0% in the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock valued at $60,000 after purchasing an additional 41 shares during the last quarter. Capital Advisors Ltd. LLC increased its stake in shares of Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after acquiring an additional 43 shares during the period. Retirement Planning Co of New England Inc. increased its position in Humana by 4.7% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock worth $245,000 after purchasing an additional 43 shares during the period. Finally, LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

NYSE:HUM traded down $1.29 during mid-day trading on Thursday, reaching $226.50. 421,409 shares of the company's stock were exchanged, compared to its average volume of 1,774,348. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a market capitalization of $27.34 billion, a PE ratio of 22.76, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The business's fifty day simple moving average is $258.76 and its two-hundred day simple moving average is $267.49. Humana Inc. has a one year low of $212.45 and a one year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. The business had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. Humana's revenue was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $7.23 earnings per share. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.56%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Oppenheimer boosted their target price on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a report on Thursday, May 1st. JPMorgan Chase & Co. lowered their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Finally, Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Seventeen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $286.81.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.